RH-PLNCT05936333
Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis
StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Jan 2025 to Oct 11, 2025
- Start date changed from estimate of Jul 2023 to Oct 11, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients diagnosed with CHI, defined by the concomitant presence of the 3 criteria required to evoke humoral alloimmune rejection for this pathology
Timeframe: up to 6 months
Secondary (6)
To measure the FSA levels by Mean Fluorescence Intensity for the different obstetrical complications: intrauterine growth retardation (IUGR), fetal death in utero and abortion for IUGR.
to measure the correlation between fetus-specific antibody level by Mean Fluorescence Intensity and the severity and/or precocity of obstetrical complications
measure of semi-quantitative graduation of C4d in placenta compared to percentage of villositis
measure of semi-quantitative graduation of CD68+ infiltrate in placenta compared to surface and number of involved villositis
To measure the expression of HLA class I and II molecules by placental villi by ß2-microglobulin and HLA-DR labelling
Show 1 moreShow less
Epitope analysis with algorithm developped by laboratoire HLA de St Louis (Pr JL Taupin)
Arms and interventions
Patient with chronic histiocytic intervillositisExperimental
Patient with CHI, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
patients with anti-phospholipid syndromes (APS)Active comparator
Patient with antiphospholipid syndrome, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
women with a third full-term pregnancy without growth retardation.Placebo comparator
Patient with normal pregnancies, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
Procedures: Biological collection
Sites
1 site in 1 country
- Antoine Béclère HospitalClamart, France